The chief executive of AstraZeneca (AZ) has told Sky News that the company’s decision to begin seeking a modest profit from its COVID vaccine is unlikely to kick in until next year.
Pascal Soriot said this was because it still had many doses of the vaccine to supply that it had promised to do so at cost.
AZ announced earlier this month that it would be seeking to achieve a modest profit in future from the vaccine In order to fund its new anti-viral COVID treatment.
But Mr Soriot stressed that, while some countries would be charged above cost for the vaccine, many more would not.
Image: The Oxford-AstraZeneca vaccine has been sold at cost since it first became available Pic: AP
He said: “You have to remember that the orders we are taking today will be delivered next year. We still have a lot of orders at no profit to deliver. So they will be delivered next year.
Advertisement
“So you have got to think of the infection as if you were already in next year. And so essentially most of the world at that point will be in a different phase. And we will be more in a regional epidemic or regional pandemic than a global pandemic.
“But you know, we will of course adapt to every circumstance and countries that have low purchasing power we will be supplied at no profit or very low price and others will be a bit more.”
More on Covid-19
Related Topics:
Mr Soriot insisted that he had no regrets that AZ had provided the vaccine at cost even though some of its competitors, such as Pfizer and Moderna, have supercharged their profits through charges for their COVID vaccines.
He went on: “We always knew that some vaccines would be sold at a profit and we made the decision from day one that we would partner with Oxford and deliver this vaccine around the world at no profit so everybody could access it much as possible.
Image: Vials of COVID vaccines made by AstraZeneca, Pfizer, Johnson and Johnson, and Sputnik V
“And again, we’ve delivered more than 2 billion doses, 30% of global supply so far, so it really has worked quite well actually. So we always knew that it was what we were going to do. So there is no surprise, so there can’t be any regret – it was our plan all along.”
He was speaking as AZ, the largest company in the FTSE 100, formally unveils The Discovery Centre, its new £1bn research and development facility in Cambridge, which will be home to some 2,200 scientists.
The centre, to be opened by the Prince of Wales today, represents the biggest single investment ever made by AZ.
It has been specifically sited in Cambridge to be at the heart of the city’s life sciences cluster, within close proximity to the Royal Papworth and Addenbrookes hospitals, Cancer Research UK and the University of Cambridge’s school of clinical medicine.
The site is referred to in scientific circles as the ‘Nobel factory’ as it has created more Nobel Prize winners than anywhere else in the world.
Mr Soriot said AZ spent around $7bn (£5.3bn) on research and development annually – of which “a large proportion”, close to one third, is deployed in the UK.
He added: “it’s a very substantial investment we make each year.”
That took the company, traditionally better known in the industry for its treatments for cancers, heart and respiratory conditions, into a fourth therapy area – and now it has decided, based on the success of its COVID vaccine roll out, to expand into a fifth, vaccines, as well.
However, asked whether AZ was trying to do too much at once, Mr Soriot insisted this was not the case.
He added: “We have great strengths in oncology and we believe we can be one of the three great companies in the world in oncology and maybe even better than that by 2025.
“We continue to do very well in cardiovascular and bio pharmaceuticals overall and now we have rare diseases and vaccines.
“What we call the vaccine and immunotherapy unit is really looking at is managing this portfolio of products to treat or vaccinate people with viral diseases.
“We want to maximise the value of these assets and manage them better.
“Now whether we invest in the long run in this field remains to be seen, but there’s a lot of synergies across this portfolio of products.”
Mr Soriot pointed out that AZ had just achieved its first quarter during which it had notched up $10bn worth of sales.
It is a significant milestone because, when Mr Soriot oversaw AZ’s successful defence against an unwanted takeover approach from Pfizer in 2014, he promised investors that AZ would be delivering annual sales of $40bn a year by 2023.
Marks & Spencer (M&S) has ordered hundreds of agency workers at its main distribution centre to stay at home as it grapples with the unfolding impact of a cyberattack on Britain’s best-known retailer.
Sky News has learnt that roughly 200 people who had been due to undertake shift work at M&S’s vast Castle Donington clothing and homewares logistics centre in the East Midlands have been told not to come in amid the escalating crisis.
Agency staff make up about 20% of Castle Donington’s workforce, according to a source close to M&S.
The retailer’s own employees who work at the site have been told to come in as usual, the source added.
“There is work for them to do,” they said.
M&S disclosed last week that it was suspending online orders as a result of the cyberattack, but has provided few other details about the nature and extent of the incident.
In its latest update to investors, the company said on Friday that its product range was “available to browse online, and our stores remain open and ready to welcome and serve customers”.
“We continue to manage the incident proactively and the M&S team – supported by leading experts – is working extremely hard to restore online operations and continue to serve customers well,” it added.
It was unclear on Monday how long the disruption to M&S’s e-commerce operations would last, although retail executives said the cyberattack was “extensive” and that it could take the company some time to fully resolve its impact.
Shares in M&S slid a further 2.4% on Monday morning, following a sharp fall last week, as investors reacted to the absence of positive news about the incident.
At that price, the company’s founder and chief executive, Will Shu, would be in line for a windfall of more than £170m.
Deliveroo further announced, before trading on Monday, that it had suspended its £100m share buyback programme.
The opening share price reaction took the value to 171p per share – still shy of the 180p on the table – and well under the 390p per share flotation price seen in 2021.
More from Money
Deliveroo’s shares have weakened nearly 50% since their market debut.
The deal is not expected to face regulatory hurdles as it provides DoorDash access to 10 new markets where it currently has no presence.
But a takeover would likely represent a blow to the City of London given the anticipated loss of a tech-focused player.
Susannah Streeter, head of money and markets at Hargreaves Lansdown, said: “If the deal is done at that price, the company will fail to shake off the ‘Floperoo’ tag it was saddled with after its disastrous IPO debut in 2021.
“Even though Deliveroo has finally broken through into profitable territory, the prolonged bout of indigestion around its share price has continued.
“The surge in demand for home deliveries during the pandemic waned just as competition heated up. Deliveroo’s foray into grocery deliveries has helped it turn a profit but it’s still facing fierce rivals.”
She added: “The DoorDash Deliveroo deal will be unappetising for the government which has been trying to boost the number of tech companies listed in London.
“If Deliveroo is purchased it would join a stream of companies leaving the London Stock Exchange, with too few IPOs [initial public offerings] in the pipeline to make up the numbers.”
A trade deal with the US is “possible” but not “certain”, a senior minister has said as he struck a cautious tone about negotiations with the White House.
Pat McFadden, the Chancellor of the Duchy of Lancaster, told Sunday Morning with Trevor Phillips there was “a serious level of engagement going on at high levels” to secure a UK-US trade deal.
However, Mr McFadden, a key ally of Sir Keir Starmer, struck a more cautious tone than Chancellor Rachel Reeves on the prospect of a US trade deal, saying: “I think an agreement is possible – I don’t think it’s certain, and I don’t want to say it’s certain, but I think it’s possible.”
He went on to say the government wanted an “agreement in the UK’s interests” and not a “hasty deal”, amid fears from critics that Number 10 could acquiesce a deal that lowers food standards, for example, or changes certain taxes in a bid to persuade Donald Trump to lower some of the tariffs that have been placed on British goods.
And asked about the timing of the deal – following recent reports an agreement was imminent – Mr McFadden said: “We’ll keep working with the United States and keep trying to get to an agreement in the coming weeks.”
As well as talks with the US, the UK has also ramped up its efforts with the EU, with suggestions it could include a new EU youth mobility scheme that would allow under-30s from the bloc to live, work and study in the UK and vice versa.
Mr McFadden said he believed the government could “improve upon” the Brexit deal struck by Boris Johnson, saying it had caused “an awful lot of bureaucracy and costs here in the UK”.
He said “first and foremost” on the government’s agenda was securing a food and agriculture and a veterinary agreement, saying it was “such an important area for the UK and an area where we’ve had so much extra cost and bureaucracy because of Brexit”.
He added: “But again, as with the United States, there’s no point in calling the game before it’s done. We’ve still got work to do, and we’re doing that work with our partners in the EU.”
The Cabinet Office minister also rejected suggestions the UK would have to choose between pursuing a trade deal with the US and one with the EU – the latter of which has banned chlorinated chicken in its markets – as has the UK – but which the US has historically wanted.
On the issue of chlorinated chicken, Mr McFadden said the government had “made clear we will not water down animal welfare standards with either party”.
“But I don’t agree that it’s some fundamental choice beyond where we have to pick one trading partner rather than another. I think that’s to misunderstand the nature of the UK economy, and I don’t think would be in our interests to put all our eggs in one basket.”
Also speaking to Trevor Phillips was Tory leader Kemi Badenoch, who said the government should be close to closing the deal with the US “because we got very close last time President Trump was in office”.
She also insisted food standards should not be watered down in order to get a deal, saying she did not reach an agreement with Canada when she was in government for that reason.
“What Labour needs to do now is show that they can get a deal that isn’t making concessions, so we can have what we had last month before the trade tariffs, and we need serious people doing this,” she said.